UK’s Drug Regulator Suspends Hydroxychloroquine Trial Recruitment.

Britain’s drug regulator on Tuesday has educated scientists trialing the utilization of malaria drug hydroxychloroquine for the treatment or prevention of COVID-19 to suspend the recruitment of participants.

As reported by Alistair Smout of the Reuters, the Medicines and Healthcare products Regulatory Agency (MHRA) said it was following “emerging concerns” about the use of the drug, and also cited a UK trial which found no meaningful mortality benefit in patients hospitalized with COVID-19.

The MHRA has made the resolution based on several other data and records evaluating the potency of the drug in nursing Covid-19 patients. MHRA CEO Dr. June Raine said: “We have told those conducting clinical trials using hydroxychloroquine to treat or prevent COVID-19 to suspend recruitment into their trials.”

“Neither hydroxychloroquine nor chloroquine are licensed to treat COVID-19 related symptoms or to prevent infection.

“It is important to note that patients taking hydroxychloroquine and chloroquine to treat other health conditions can continue to do so, as advised by their healthcare professional, as the balance of benefits and risks remains favorable in the licensed uses.”

The efficacy of the drug has been under review across the globe with many countries reexamining the use of HCQ for the treatment of Covid-19 patients.

The US Food and Drug Administration (USFDA), for example, reversed the emergency use authorization (EUA) for HCQ on Monday. The government agency in a directive had said that hydroxychloroquine and chloroquine were “unlikely” to be efficacious for the fight against Covid-19.

“Additionally, in light of the ongoing serious cardiac adverse events and other potential serious side-effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use,” the USFDA had said.

Donald Trump last month said he had been taking the hydroxychloroquine as a way of warding off the virus after becoming concerned that White House staff may have become infected.

Already authorized to fight malaria and certain autoimmune diseases, there are some side effects linked with hydroxychloroquine, including disturbed heart rhythm.

Reporting by Winsala Gbotemi, Staff Writer EGM.

Create Your Trading Account!

Originally published at https://www.egmanalytics.com on June 17, 2020.